# Silence Therapeutics plc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Silence Therapeutics plc). ## Overview Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference. The company is headquartered in London, operates as a UK public limited company, and has its ADSs listed on Nasdaq in the United States. ## Products & services • siRNA drug discovery and development • mRNAi GOLD™ liver-targeting platform • RNAi product candidates for rare diseases • RNAi product candidates for common diseases • Collaboration and licensing of RNAi targets - **siRNA therapeutics platform** (70%) — Discovery and development of short interfering RNA molecules designed to silence specific genes. - **Collaboration licenses and options** (30%) — Out-licensing of RNAi targets and programs to pharmaceutical partners under collaboration agreements. - siRNA drug discovery and development - mRNAi GOLD™ liver-targeting platform - RNAi product candidates for rare diseases - RNAi product candidates for common diseases - Collaboration and licensing of RNAi targets ## Customers Silence Therapeutics primarily sells to large pharmaceutical partners through collaboration and licensing agreements rather than to end patients. Its partners use the company’s RNAi programs and target rights to advance drug development in defined therapeutic areas and geographies. If approved in the future, its medicines would ultimately be used by physicians, patients, and third-party payers in the relevant disease markets. - **Pharmaceutical collaboration partners** (primary) — License RNAi targets and programs to advance internal pipelines and share development rights. - **Biotech development partners** (primary) — Partner on specific targets or programs where Silence contributes platform technology and discovery capability. - **Future physicians and specialty clinics** (emerging) — Would prescribe approved therapies in rare or specialty disease settings if products reach market. - **Patients and caregivers** (emerging) — End users of any approved RNAi medicines, especially in diseases with limited treatment options. - **Payers and reimbursement authorities** (emerging) — Determine coverage and reimbursement for any commercialized therapies, affecting adoption. - Large pharma partners licensing RNAi targets and programs - Biopharma collaborators funding development milestones - Potential future prescribers in specialty disease markets - Patients with rare or high-unmet-need diseases - Third-party payers that determine reimbursement access ## Geography Silence Therapeutics is based in London and maintains a corporate presence in the United Kingdom, with additional operations and office rental exposure in Berlin and the United States. Its collaboration model is global in scope, including worldwide licenses and a Greater China, Hong Kong, Macau and Taiwan option structure with Hansoh. Commercialization, if achieved, is intended for the United States and other key markets. - **United Kingdom** (40%) — Corporate headquarters and principal executive offices - **United States** (35%) — Nasdaq listing, U.S. operations, and key future commercialization market - **Germany** (15%) — Berlin office and operating presence - **Greater China / Hong Kong / Macau / Taiwan** (10%) — Region covered by Hansoh option rights - Headquartered in London, United Kingdom - Berlin office supports research and operating activities - United States is a key corporate and capital markets base - Collaboration rights can be worldwide or region-specific - Greater China is relevant through the Hansoh agreement ## Strategy Silence Therapeutics is focused on advancing its siRNA platform into partnered and proprietary programs aimed at diseases with significant unmet need. The company’s strategy relies on using collaborations to validate the platform, fund development, and expand the number of RNAi targets while preserving optionality for future commercialization. It also intends to build commercial capabilities only if and when product candidates reach approval. - **Grow the RNAi pipeline** (medium-term) — A broader pipeline increases partnering opportunities and future product optionality. - **Secure and expand collaborations** (short-term) — Partner funding helps offset development costs and validates target selection. - **Advance clinical-stage programs** (medium-term) — Clinical progress is required to create value and support future approvals. - **Prepare for future commercialization** (long-term) — Approved products would require sales, distribution, reimbursement, and manufacturing capabilities. - Advance siRNA programs against high-unmet-need disease targets - Use collaborations to fund development and validate the platform - Expand the pipeline through the mRNAi GOLD™ discovery engine - Retain future commercialization optionality in key markets - Rely on external manufacturing and partnership structures ## Risks The company faces the typical risks of a clinical-stage biotech: development failure, regulatory delays, and dependence on third-party collaborators, manufacturers, and payers. It also has exposure to data privacy and security obligations, foreign exchange movements, and the challenge of proving that RNAi medicines can achieve market acceptance and reimbursement. - **Pipeline and clinical development failure** [high] — The business depends on proving that siRNA candidates are safe and effective in humans. - **Partner concentration and collaboration dependence** [high] — A significant portion of revenue comes from collaboration agreements and milestones. - **Reimbursement and market access risk** [medium] — Even approved RNAi therapies may face payer resistance or pricing pressure. - **Manufacturing and supply chain constraints** [medium] — The company does not own manufacturing facilities and relies on cGMP contractors. - **Data privacy and security compliance** [medium] — Failure to comply with evolving privacy laws can lead to investigations, fines, and disruption. - Clinical programs may fail to show safety or efficacy - Collaborations may not deliver expected milestones or royalties - Commercial adoption depends on payer coverage and reimbursement - Third-party CRO and manufacturer dependence can disrupt timelines - Data privacy and security failures can trigger fines and litigation ## Accounting The most important accounting judgment is revenue recognition under collaboration agreements, where milestone and license revenue depends on contract terms and performance obligations. Investors should also watch estimates around clinical and manufacturing commitments, foreign currency effects, and any future impairment or valuation issues as the pipeline matures. - **Revenue recognition under collaboration agreements** — Affects quarterly revenue volatility and comparability - **Clinical and manufacturing commitments** — Affects expense recognition and cash planning - **Foreign currency translation and transaction gains/losses** — Can materially affect reported earnings and cash flow - **Valuation of short-term investments** — Affects other income and liquidity presentation - Collaboration revenue depends on milestone and license accounting - Revenue timing can shift with partner activity and contract terms - Clinical CRO and manufacturing commitments create estimate risk - Foreign currency movements affect reported results and cash - Future impairment risk may arise if programs lose value --- *Last updated: 2026-04-29T04:58:34.493426+00:00*